

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Agency for Healthcare Research and Quality****Meeting of the National Advisory Council for Healthcare Research and Quality**

**AGENCY:** Agency for Healthcare Research and Quality (AHRQ), Department of Health and Human Services.

**ACTION:** Notice of public meeting.

**SUMMARY:** This notice announces a meeting of the National Advisory Council for Healthcare Research and Quality.

**DATES:** The meeting will be held on Monday, March 6, 2023, from 11:30 a.m. to 3:00 p.m.

**ADDRESSES:** The meeting will be held virtually.

**FOR FURTHER INFORMATION CONTACT:**

Jaime Zimmerman, Designated Management Official, at the Agency for Healthcare Research and Quality, 5600 Fishers Lane, Mail Stop 06E37A, Rockville, Maryland 20857, (301) 427-1456. For press-related information, please contact Bruce Seeman at (301) 427-1998 or [Bruce.Seeman@AHRQ.hhs.gov](mailto:Bruce.Seeman@AHRQ.hhs.gov).

Closed captioning will be provided during the meeting. If another reasonable accommodation for a disability is needed, please contact the Food and Drug Administration (FDA) Office of Equal Employment Opportunity and Diversity Management on (301) 827-4840, no later than Monday, February 27, 2023. The agenda, roster, and minutes will be available from Jenny Griffith, Committee Management Officer, Agency for Healthcare Research and Quality, 5600 Fishers Lane, Rockville, Maryland 20857. Jenny Griffith's phone number is (240) 446-6799.

**SUPPLEMENTARY INFORMATION:****I. Purpose**

In accordance with section 10(a) of the Federal Advisory Committee Act, 5 U.S.C. App., this notice announces a meeting of the National Advisory Council for Healthcare Research and Quality (the Council). The Council is authorized by Section 941 of the Public Health Service Act, 42 U.S.C. 299c. In accordance with its statutory mandate, the Council is to advise the Secretary of the Department of Health and Human Services and the Director of AHRQ on matters related to AHRQ's conduct of its mission including providing guidance on (A) priorities for health care research,

(B) the field of health care research including training needs and information dissemination on health care quality and (C) the role of the Agency in light of private sector activity and opportunities for public private partnerships. The Council is composed of members of the public, appointed by the Secretary, and Federal ex-officio members participating in the authorizing legislation.

**II. Agenda**

On Monday, March 6, 2023, NAC members will meet to conduct preparatory work prior to convening the Council meeting at 11:30 a.m., with the call to order by the Council Chair, an introduction of NAC members, and approval of previous Council summary notes. The NAC members will then receive an update from the AHRQ Director, including a follow up discussion on private capital and engaging health system executive leadership. The agenda will also include (1) an update and discussion by NAC members on AHRQ's Patient Safety Framework and the Patient Safety Action Alliance's efforts to promote Safer Together: A National Patient Safety Action Plan and (2) a report out and discussion about Long Covid and addressing health system fragmentation. The meeting is open to the public and will adjourn at 3:00 p.m. For information regarding how to access the meeting as well as other meeting details, including information on how to make a public comment, please go to <https://www.ahrq.gov/news/events/nac/>. The final agenda will be available on the AHRQ website no later than Monday February 27, 2023.

Dated: February 3, 2023.

**Marquita Cullom,**

*Associate Director.*

[FR Doc. 2023-02724 Filed 2-8-23; 8:45 am]

**BILLING CODE 4160-90-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Agency for Toxic Substances and Disease Registry**

[Docket No. ATSDR-2022-0006]

**Availability of Four Draft Toxicological Profiles**

**AGENCY:** Agency for Toxic Substances and Disease Registry (ATSDR), Department of Health and Human Services (HHS).

**ACTION:** Notice with comment period.

**SUMMARY:** The Agency for Toxic Substances and Disease Registry

(ATSDR), within the Department of Health and Human Services (HHS), announces the opening of a docket to obtain comments on drafts of four updated toxicological profiles: Cobalt, Hexachlorocyclohexanes, 1,1,1-Trichloroethane, and Vinyl Chloride.

**DATES:** Written comments must be received on or before May 10, 2023.

**ADDRESSES:** You may submit comments, identified by Docket Number ATSDR-2022-0006, by either of the following methods:

- *Federal eRulemaking Portal:* [www.regulations.gov](http://www.regulations.gov). Follow the instructions for submitting comments.

- *Mail:* Toxicology Section, Office of Innovation and Analytics, Agency for Toxic Substances and Disease Registry, 4770 Buford Highway, Mail Stop S102-1, Atlanta, GA 30341-3717. Attn: Docket No. ATSDR-2022-0006.

*Instructions:* All submissions must include the Agency name and Docket Number. All relevant comments received will be posted without change to [www.regulations.gov](http://www.regulations.gov), including any personal information provided. Do not submit comments by email. ATSDR does not accept comments by email. For access to the docket to read background documents or comments received, go to [www.regulations.gov](http://www.regulations.gov).

**FOR FURTHER INFORMATION CONTACT:** N. Roney, Agency for Toxic Substances and Disease Registry, 4770 Buford Highway, Mail Stop S102-1, Atlanta, GA 30329-4027; Email: [ATSDRToxProfileFRNs@cdc.gov](mailto:ATSDRToxProfileFRNs@cdc.gov); Telephone: 800-232-4636.

**SUPPLEMENTARY INFORMATION:** ATSDR has prepared drafts of four updated toxicological profiles based on current understanding of the health effects and availability of new studies and other information since their initial release. All toxicological profiles issued as "Drafts for Public Comment" represent the result of ATSDR's evidence-based evaluations to provide important toxicological information on priority hazardous substances to the public and health professionals. ATSDR considers key studies for these substances during the profile development process, using a systematic review approach. To that end, ATSDR is seeking public comments and additional information or reports on studies about the health effects of these four substances for review and potential inclusion in the profiles. ATSDR will evaluate the quality and relevance of such data or studies for possible inclusion in the profile.